Cited by

• Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.

  Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. Dufort S, et al. J Exp Clin Cancer Res. 2011 May 16;30(1):57. doi: 10.1186/1756-9966-30-57. J Exp Clin Cancer Res. 2011. PMID: 21575212 Free PMC article.
• Survival and death signals can predict tumor response to therapy after oncogene inactivation.

  Tran PT, Bendapudi PK, Lin HJ, Choi P, Koh S, Chen J, Horng G, Hughes NP, Schwartz LH, Miller VA, Kawashima T, Kitamura T, Paik D, Felsher DW. Tran PT, et al. Sci Transl Med. 2011 Oct 5;3(103):103ra99. doi: 10.1126/scitranslmed.3002018. Sci Transl Med. 2011. PMID: 21974937 Free PMC article.
• Imaging: Mass spectrometry in HNSCC--a peek at response prediction?

  Ang MK, Hayes DN. Ang MK, et al. Nat Rev Clin Oncol. 2010 Apr;7(4):193-5. doi: 10.1038/nrclinonc.2010.35. Nat Rev Clin Oncol. 2010. PMID: 20354544
• An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).

  Quinton C, Ellis PM. Quinton C, et al. Cancers (Basel). 2011 Sep 13;3(3):3506-24. doi: 10.3390/cancers3033506. Cancers (Basel). 2011. PMID: 24212966 Free PMC article.
• Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

  Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV, Cognetti F, Giannarelli D. Bria E, et al. Ann Oncol. 2011 Oct;22(10):2277-85. doi: 10.1093/annonc/mdq742. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325444 Free PMC article. Review.